Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Investing Activities: 2021-2025

Historic Cash from Investing Activities for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to -$62.8 million.

  • Kiniksa Pharmaceuticals International's Cash from Investing Activities fell 888.58% to -$62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.9 million, marking a year-over-year decrease of 24.39%. This contributed to the annual value of $37.7 million for FY2024, which is 227.46% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Cash from Investing Activities stood at -$62.8 million for Q3 2025, which was down 1,516.15% from -$3.9 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Cash from Investing Activities high stood at $86.0 million for Q2 2021, and its period low was -$62.8 million during Q3 2025.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Cash from Investing Activities averaged around -$10.0 million, with its median value being -$12.3 million (2023).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 538.38% in 2024, then plummeted by 888.58% in 2025.
  • Kiniksa Pharmaceuticals International's Cash from Investing Activities (Quarterly) stood at -$50.0 million in 2021, then increased by 14.75% to -$42.7 million in 2022, then spiked by 65.09% to -$14.9 million in 2023, then skyrocketed by 538.38% to $65.3 million in 2024, then slumped by 888.58% to -$62.8 million in 2025.
  • Its Cash from Investing Activities stands at -$62.8 million for Q3 2025, versus -$3.9 million for Q2 2025 and -$51.5 million for Q1 2025.